<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628884</url>
  </required_header>
  <id_info>
    <org_study_id>DIB-20-34</org_study_id>
    <nct_id>NCT04628884</nct_id>
  </id_info>
  <brief_title>Strategies for Protamine Dosing After Anticoagulation in Cardiovascular Surgery</brief_title>
  <acronym>SEPARATION</acronym>
  <official_title>Comparison of Two Strategies for Protamine Dosing After Anticoagulation in Cardiovascular Surgery Regarding Postoperative Bleeding: Total Heparin Administered Versus Residual Heparin Determined by a Pharmacokinetic Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Clínica Shaio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad El Bosque, Bogotá</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Clínica Shaio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In cardiovascular surgery, patients are anticoagulated with heparin during cardiopulmonary&#xD;
      bypass, subsequently, anticoagulation is reversed with protamine to reduce bleeding due to&#xD;
      residual heparin-induced coagulopathy, which can last more than four hours. Protamine&#xD;
      reverses the effect of heparin by binding to each heparin molecule, therefore an amount of&#xD;
      protamine equivalent to residual heparin is required at the time that anticoagulation is&#xD;
      desired to be reversed, but generally, the dose of protamine is calculated from the total&#xD;
      dose of heparin, ignoring that heparin is metabolized and cleared during of the&#xD;
      extracorporeal circulation, this excess of protamine produces anticoagulant effects that&#xD;
      increase postoperative bleeding. Residual heparin can be estimated from heparin&#xD;
      pharmacokinetic models and therefore, from these models, a dose closer to the amount&#xD;
      necessary to reverse the effect of heparin can be estimated, avoiding protamine excess. In&#xD;
      this study, a protamine dosage strategy based on residual heparin determined by a&#xD;
      pharmacokinetic model of heparin versus total administered heparin will be compared regarding&#xD;
      bleeding and use of blood components in the postoperative period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">November 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative mediastinal bleeding</measure>
    <time_frame>first 24 hours after surgery</time_frame>
    <description>total blood collected from the mediastinal chest tubes during the first 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total blood products transfused</measure>
    <time_frame>first 24 hours after surgery</time_frame>
    <description>red blood cells, plasma, cryoprecipitate, platelets, fibrinogen, and prothrombin complexes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Anticoagulant Antagonist Toxicity</condition>
  <arm_group>
    <arm_group_label>Protamine dosing according the total heparin administrated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The protamine dose will be calculated according to the total heparin administered including the heparin dose add during the pump purge, 1 mg of protamine for each 100 IU of heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protamine dosing according the residual heparin determined by a pharmacokinetic model</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The protamine dose will be calculated according to the residual heparin estimated before the separation of the cardiopulmonary bypass using a pharmacokinetic model, 1 mg of protamine for each 100 IU of residual heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional dose</intervention_name>
    <description>Conventional dose used to calculated the protamine dose</description>
    <arm_group_label>Protamine dosing according the total heparin administrated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dosing according residual heparin</intervention_name>
    <description>In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin</description>
    <arm_group_label>Protamine dosing according the residual heparin determined by a pharmacokinetic model</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age who undergo scheduled cardiovascular surgery or&#xD;
             scheduled urgency at the Shaio clinical foundation in the city of Bogotá, who require&#xD;
             extracorporeal circulation.&#xD;
&#xD;
          -  ASA classification, between 1 - 4&#xD;
&#xD;
          -  Informed consent read and signed by the patient&#xD;
&#xD;
          -  No history of known blood dyscrasia, with INR values &lt;1.5&#xD;
&#xD;
          -  Platelet count greater than 100,000&#xD;
&#xD;
          -  No history of heparin-induced thrombocytopenia&#xD;
&#xD;
          -  No history of adverse reaction to protamine&#xD;
&#xD;
          -  No use of dual anti-aggregation therapy acetylsalicylic acid (ASA) + ADP receptor&#xD;
             inhibitors (Clopidogrel) at the time of surgery&#xD;
&#xD;
          -  Suspension of ADP receptor inhibitor drugs (Clopidogrel) according to institutional&#xD;
             protocol.&#xD;
&#xD;
          -  No use of bridging therapy with tirofiban&#xD;
&#xD;
          -  Patient with chronic use of oral anticoagulants (warfarin, dabigatran), complete the&#xD;
             suspension time according to the institutional protocol,&#xD;
&#xD;
          -  No requirement for renal replacement therapy in the last month&#xD;
&#xD;
          -  Patient with BMI between 18 - 41 kg / cm2&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Anticoagulated patient at the time of the intervention&#xD;
&#xD;
          -  Procedure not performed under extracorporeal circulation.&#xD;
&#xD;
          -  Procedure requiring circulatory arrest and / or profound hypothermia&#xD;
&#xD;
          -  Intraoperative death before protamine administration&#xD;
&#xD;
          -  Inability to complete data collection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Abello</last_name>
    <role>Study Chair</role>
    <affiliation>Fundacion Abood Shaio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Ramez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad del bosque</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabian Cortez, MSc</last_name>
    <phone>+57 (1) 593 8210</phone>
    <email>fabian.cortes@shaio.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundacion Abood Shaio</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Abello</last_name>
      <phone>+57 3103218780</phone>
      <email>mauricio.abello@shaio.org</email>
    </contact>
    <investigator>
      <last_name>David Ramirez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Puis L, Milojevic M, Boer C, De Somer FMJJ, Gudbjartsson T, van den Goor J, Jones TJ, Lomivorotov V, Merkle F, Ranucci M, Kunst G, Wahba A; EACTS/EACTA/EBCP Committee Reviewers. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Interact Cardiovasc Thorac Surg. 2020 Feb 1;30(2):161-202. doi: 10.1093/icvts/ivz251.</citation>
    <PMID>31576402</PMID>
  </reference>
  <reference>
    <citation>Delavenne X, Ollier E, Chollet S, Sandri F, Lanoiselée J, Hodin S, Montmartin A, Fuzellier JF, Mismetti P, Gergelé L. Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass. Br J Anaesth. 2017 May 1;118(5):705-712. doi: 10.1093/bja/aex044.</citation>
    <PMID>28510738</PMID>
  </reference>
  <reference>
    <citation>Meesters MI, Veerhoek D, de Jong JR, Boer C. A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth. 2016 Oct;30(5):1190-5. doi: 10.1053/j.jvca.2016.04.021. Epub 2016 Apr 28.</citation>
    <PMID>27493093</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heparin</keyword>
  <keyword>protamine</keyword>
  <keyword>dose</keyword>
  <keyword>extracorporeal circulation</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

